McKesson Corporation — Wall Street Analyst Estimates & Price Targets

MCK

NYSEHealthcareMedical - DistributionCIK 0000927653mckesson.comAbout MCK

Last close · Oct 16, 20261,004.84+6.20 (+0.62%)

Market cap$117.2B

6 firms' latest targets, last 90 days: median $988.50 ($845.00–$1,200.00), 2% below the last close.

Price and published targets

daily close, 12 months · each dot a target, a firm's latest darker

Each firm's latest target

last 90 days · 6 firms

Date	Firm	Target	Previous	Change	Vs price then	Vs price now
2026-10-16	UBS	$1,200.00	$1,050.00	▲ 14%	+20%	+19%
2026-10-06	Morgan Stanley	$977.00	$966.00	▲ 1%	+7%	-3%
2026-08-19	Barclays	$1,000.00	$1,050.00	▼ 5%	+15%	+0%
2026-08-19	RBC Capital	$845.00	—	—	-3%	-16%
2026-08-11	Wells Fargo	$933.00	—	—	+6%	-7%
2026-08-06	Baird	$1,015.00	$968.00	▲ 5%	+20%	+1%

Consensus estimates

revenue and EPS by fiscal year · reported years marked

FY	Revenue	YoY	EPS	YoY	Revenue range	EPS range	Analysts
2024reported	$309.0B	+12%	$22.39	-11%	est. $311.9B-1%	est. $27.61	11
2025reported	$359.1B	+16%	$25.72	+15%	est. $362.6B-1%	est. $32.78	10
2026reported	$403.4B	+12%	$38.38	+49%	est. $408.5B-1%	est. $39.01	13
2027	$431.9B	+7%	$44.65	+14%	$410.1B–$435.9B	$44.24–$45.17	10
2028	$461.3B	+7%	$50.67	+13%	$433.6B–$477.8B	$47.46–$51.54	10
2029	$494.5B	+7%	$58.10	+15%	$468.9B–$530.5B	$55.99–$59.94	10
2030	$515.5B	+4%	$66.48	+14%	$497.3B–$529.7B	$63.44–$68.87	5
2031	$560.3B	+9%	$80.34	+21%	$540.6B–$575.8B	$76.66–$83.22	4

A reported year shows the company's figures, with the consensus beside it (revenue against it in %). Reported EPS is GAAP diluted; the analysts' EPS usually leaves items such as stock compensation out, so the two are not like for like. Faded: a year the valuation models do not read — they read the first 3, and a later one only while 10 or more analysts cover every year up to it — or one under 5 analysts.

The analysts at a glance

$988.50median target, 2% below the last close

Firms with a target · last 90 days: 6
Lowest – highest target: $845.00 – $1,200.00
Current grades of 13 firms: positive / neutral / negative: 10 / 3 / 0
Upgrades / downgrades · 12 months: 0 / 0
Consensus revenue growth · next 3 FY: +7% a year

Current grades

each firm's latest · 13 firms

As of	Firm	Grade
2026-10-16	UBS	“Buy”
2026-10-07	Leerink Partners	“Outperform”
2026-09-14	RBC Capital	“Sector Perform”
2026-08-19	Barclays	“Overweight”
2026-08-11	Wells Fargo	“Equal Weight”
2026-08-06	TD Cowen	“Buy”
2026-08-06	Evercore ISI	“Outperform”
2026-07-24	Citigroup	“Buy”
2026-05-08	J.P. Morgan	“Overweight”
2026-04-06	Bank of America	“Buy”

3 more

2026-02-05	Mizuho	“Neutral”
2025-11-06	Morgan Stanley	“Overweight”
2025-11-06	Baird	“Outperform”

Grade changes

last 24 months · 1

Date	Firm	Grade
2024-11-07	Baird	“Neutral” → “Outperform” upgrade

45 older than 24 months

2024-09-24	Baird	“Outperform” → “Neutral” downgrade
2022-06-07	Deutsche Bank	“Hold” → “Buy” upgrade
2022-02-04	Deutsche Bank	“Buy” → “Hold” downgrade
2022-01-07	Credit Suisse	“Neutral” → “Outperform” upgrade
2021-03-30	Argus Research	“Hold” → “Buy” upgrade
2020-11-02	Barclays	“Equal Weight” → “Overweight” upgrade
2020-08-04	Deutsche Bank	“Hold” → “Buy” upgrade
2020-05-15	UBS	“Neutral” → “Buy” upgrade
2020-03-18	Goldman Sachs	“Neutral” → “Buy” upgrade
2020-02-07	Baird	“Neutral” → “Outperform” upgrade
2020-01-10	Morgan Stanley	“Equal Weight” → “Overweight” upgrade
2019-01-25	Deutsche Bank	“Sell” → “Hold” upgrade
2018-07-20	Baird	“Outperform” → “Neutral” downgrade
2018-07-10	Standpoint Research	“Hold” → “Buy” upgrade
2018-01-24	Jefferies	“Hold” → “Buy” upgrade
2017-10-10	TD Cowen	“Market Perform” → “Outperform” upgrade
2017-09-19	Baird	“Neutral” → “Outperform” upgrade
2017-09-19	RBC Capital	“Sector Perform” → “Perform” revised
2017-09-14	Morgan Stanley	“Overweight” → “Equal Weight” downgrade
2017-07-28	Jefferies	“Hold” → “Buy” upgrade
2017-05-23	J.P. Morgan	“Neutral” → “Overweight” upgrade
2017-01-18	Avondale Partners	“Market Perform” → “Market Outperform” upgrade
2017-01-05	J.P. Morgan	“Overweight” → “Neutral” downgrade
2017-01-03	Mizuho	“Buy” → “Neutral” downgrade
2016-11-23	Credit Suisse	“Neutral” → “Underperform” downgrade
2016-11-11	Standpoint Research	“Buy” → “Hold” downgrade
2016-11-09	Mizuho	“Neutral” → “Buy” upgrade
2016-10-28	Leerink Partners	“Outperform” → “Market Perform” downgrade
2016-10-27	Baird	“Outperform” → “Neutral” downgrade
2016-09-16	Goldman Sachs	“Buy” → “Neutral” downgrade
2016-05-05	Avondale Partners	“Market Outperform” → “Market Perform” downgrade
2016-04-26	Standpoint Research	“Buy” → “Hold” downgrade
2016-04-18	Avondale Partners	“Market Perform” → “Perform” revised
2016-03-15	TD Cowen	“Outperform” → “Market Perform” downgrade
2016-03-01	Mizuho	“Buy” → “Neutral” downgrade
2016-02-10	Standpoint Research	“Hold” → “Buy” upgrade
2016-01-12	Raymond James	“Market Perform” → “Perform” revised
2016-01-06	Raymond James	“Strong Buy” → “Outperform” downgrade
2014-01-13	S&P Capital IQ	“Strong Buy” → “Buy” downgrade
2014-01-06	Raymond James	“Outperform” → “Strong Buy” upgrade
2013-10-25	Morgan Stanley	“Equal Weight” → “Overweight” upgrade
2013-10-24	Evercore ISI	“Buy” → “Strong Buy” upgrade
2013-10-09	Raymond James	“Market Perform” → “Hold” revised
2012-09-05	Mizuho	“Neutral” → “Buy” upgrade
2012-08-17	Morgan Stanley	“Overweight” → “Equal Weight” downgrade

Targets, grades and estimates are quoted from third parties (via Financial Modeling Prep) and are theirs, not ours; each target links to the report it was published in. A firm counts once, at its latest target or grade.